Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968372 | 0.91 | PTGER3 (0.41) | FFAR1TP53NFKB1SMN1; SMN2ALOX5 | |
| SCHEMBL2785504 | 0.89 | CYSLTR2 (0.40) | FFAR1TP53NFKB1SMN1; SMN2ALOX5 | |
| SCHEMBL2107789 | 0.89 | MRGPRX4 (0.44) | MRGPRX4FFAR1ALOX5 | |
| SCHEMBL6155468 | 0.87 | NPC1 (0.42) | FFAR1ALOX5 | |
| SCHEMBL6155616 | 0.87 | ALOX5 (0.39) | FFAR1TP53NFKB1SMN1; SMN2ALOX5 | |
| SCHEMBL6155510 | 0.86 | MAPK1 (0.39) | FFAR1TP53NFKB1SMN1; SMN2ALOX5 | |
| SCHEMBL2106606 | 0.84 | VDR (0.43) | MRGPRX4PTGER3 | |
| SCHEMBL6154987 | 0.78 | PTGER3 (0.34) | MRGPRX4FFAR1PTGER3 | |
| SCHEMBL6154985 | 0.78 | PTGER3 (0.35) | MRGPRX4FFAR1ALOX5PTGER3 | |
| SCHEMBL6155463 | 0.78 | VDR (0.44) | MRGPRX4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2007-02-22 | — | — | US | claimed |
| EP-1686972-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | Galderma Research & Development, S.N.C. (FR) | 2006-08-09 | — | — | EP | claimed |
| WO-2005053666-A1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-16 | — | — | WO | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| US-11730682-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-2836187-B1 | SELF-STANDING COSMETIC SHEET | OREAL (FR) | 2021-12-08 | — | — | EP | disclosed |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2018-08-23 | — | — | US | disclosed |
| US-9949897-B2 | Self-standing cosmetic sheet | L'OREAL (FR) | 2018-04-24 | — | — | US | disclosed |
| US-20150209243-A1 | SELF-STANDING COSMETIC SHEET | L'OREAL (FR) | 2015-07-30 | — | — | US | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | L'OREAL (FR) | 2002-12-26 | — | — | US | disclosed |
| EP-1262168-A1 | Composition containing fibres to combat the skin aging process | L'OREAL (FR) | 2002-12-04 | — | — | EP | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020197289-A1 | Compositions and methods for combating the appearance of ageing | CYP24A1, CYP27B1, CYP2R1 | MRGPRX4 2961/4885FFAR1 3676/4885TP53 2959/4885 |
| US-20070041910-A1 | Pharmaceutical spray compositions comprising a bioactive agent, at least one volatile silicone and a non-volatile oily phase | CYP24A1, CYP2R1, VDR | MRGPRX4 1709/4885FFAR1 91/4885TP53 1813/4885 |
| US-20090004232-A1 | BIOACTIVE PHARMACEUTICAL/COSMETIC COMPOSITIONS AND MIXED SOLUBILIZATION PROCESS FOR THE FORMULATION THEREOF | CYP19A1, CYP17A1, CYP51A1 | MRGPRX4 155/4885FFAR1 22/4885TP53 2025/4885 |
| US-20150209243-A1 | SELF-STANDING COSMETIC SHEET | CUTA, SUCLG1, SIGLEC7 | MRGPRX4 3360/4885FFAR1 972/4885TP53 2002/4885 |
| US-20180235849-A1 | SELF-STANDING COSMETIC SHEET | CUTA, DSG1, SUCLG1 | MRGPRX4 2825/4885FFAR1 1727/4885TP53 775/4885 |
| US-11730682-B2 | Self-standing cosmetic sheet | CUTA, DSG1, SUCLG1 | MRGPRX4 2825/4885FFAR1 1727/4885TP53 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.